Norden Group LLC Grows Stock Position in Johnson & Johnson $JNJ

Norden Group LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 11.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,960 shares of the company’s stock after purchasing an additional 3,540 shares during the period. Norden Group LLC’s holdings in Johnson & Johnson were worth $6,297,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Fiduciary Planning LLC increased its position in shares of Johnson & Johnson by 7.0% during the third quarter. Fiduciary Planning LLC now owns 4,487 shares of the company’s stock worth $832,000 after acquiring an additional 294 shares during the last quarter. World Investment Advisors raised its position in shares of Johnson & Johnson by 2.7% in the 3rd quarter. World Investment Advisors now owns 134,893 shares of the company’s stock valued at $25,012,000 after purchasing an additional 3,498 shares in the last quarter. Triangle Securities Wealth Management boosted its stake in shares of Johnson & Johnson by 9.1% during the 3rd quarter. Triangle Securities Wealth Management now owns 19,360 shares of the company’s stock valued at $3,590,000 after buying an additional 1,611 shares during the last quarter. Symmetry Partners LLC increased its stake in shares of Johnson & Johnson by 12.3% in the third quarter. Symmetry Partners LLC now owns 7,273 shares of the company’s stock worth $1,348,000 after buying an additional 797 shares during the last quarter. Finally, Global X Japan Co. Ltd. raised its holdings in Johnson & Johnson by 384.4% in the third quarter. Global X Japan Co. Ltd. now owns 19,789 shares of the company’s stock valued at $3,669,000 after acquiring an additional 15,704 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. HSBC reissued a “buy” rating and issued a $240.00 price objective on shares of Johnson & Johnson in a report on Wednesday, December 10th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Stifel Nicolaus lifted their price target on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. UBS Group lifted their target price on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Finally, Barclays increased their target price on shares of Johnson & Johnson from $176.00 to $197.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Four analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $210.25.

Johnson & Johnson Price Performance

NYSE JNJ opened at $207.54 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $215.18. The company has a market cap of $500.02 billion, a PE ratio of 20.03, a PEG ratio of 2.25 and a beta of 0.36. The stock’s 50-day moving average price is $199.67 and its two-hundred day moving average price is $180.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion for the quarter. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.